Learn about Vancocin Capsules

What are Vancocin Capsules?

Vancocin^® HCl Capsules (vancomycin hydrochloride capsules, USP) are the capsule form of vancomycin hydrochloride. Vancomycin hydrochloride is an antibacterial agent. It kills susceptible bacteria by weakening their cell wall structure. This causes the bacteria's cell wall to break open and the organism to die.

What are Vancocin Capsules used to treat?

Vancocin Capsules are used to treat two bacterial infections that affect part of the gastrointestinal tract called the colon.

Vancocin Capsules may be administered orally for the treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).

For full prescribing information, click here.

How should I take Vancocin Capsules?

Vancocin Capsules should be taken as directed by your physician. The usual dose in adults is 500 mg to 2 g administered by mouth in 3 or 4 divided doses for 7 to 10 days. The usual dosage in pediatric patients is a daily dosage of 40 mg/kg divided into 3 or 4 doses for 7 to 10 days. The total daily dose in children should not exceed 2 g.

Skipping doses or not completing the full course of therapy may decrease the effectiveness of the immediate treatment and increase the likelihood that bacteria will develop resistance and will not be treatable by Vancocin Capsules or other antibacterial drugs in the future.

What are the possible side effects of Vancocin Capsules?

For a full description of side effects, precautions, and contraindications associated with Vancocin Capsules click here.

How are Vancocin Capsules supplied?

Vancocin Capsules are available only by prescription. Vancocin Capsules are available as a 125 mg and 250 mg capsule.

For full prescribing information, click here.

VANCOCIN HCl Capsules may be administered orally for treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by Clostridium difficile. Parenteral administration of vancomycin is not effective for the above indications; therefore, VANCOCIN HCl Capsules must be given orally for these indications. Orally administered VANCOCIN HCl Capsules are not effective for other types of infection.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancocin Capsules and other antibacterial drugs, Vancocin Capsules should only be used to treat or prevent infections that are proven or strongly suspected to be caused by a susceptible bacteria. When culture and sensitivity are available, they should be considered in selecting or modifying antibacterial therapy.

Adverse events include nephrotoxicity, ototoxicity, reversible neutropenia, thrombocytopenia, and “Red Man’s Syndrome”. In patients with renal dysfunction or those receiving concomitant therapy with an aminoglycoside, serial renal function testing should be performed. In patients receiving concomitant therapy with another ototoxic agent, serial tests of auditory function may be helpful in order to minimize the risk of ototoxicity. Infrequently allergic reation, including anaphylaxis, and exfoliative dermatitis have been reported.

Clinically significant serum concentrations of vancomycin have been reported in some patients treated with Vancocin capsules for pseudomembranous colitis caused by Clostridium difficile. It is noteworthy that total systemic and renal clearance of vancomcyin are reduced in the elderly. Monitoring of serum concentrations may be appropriate in patients with renal insufficiency and/or colitis.

Vancocin capsules are contraindicated in patients with a known hypersensitivity to vancomycin.



Learn about Vancocin Capsules What are Vancocin Capsules? Vancocin^® HCl Capsules (vancomycin hydrochloride capsules, USP) are the capsule form of vancomycin hydrochloride. Vancomycin hydrochloride is an antibacterial agent. It kills susceptible bacteria by weakening their cell wall structure. This causes the bacteria's cell wall to break open and the organism to die. What are Vancocin Capsules used to treat? Vancocin Capsules are used to treat two bacterial infections that affect part of the gastrointestinal tract called the colon. Vancocin Capsules may be administered orally for the treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains). For full prescribing information, click here. How should I take Vancocin Capsules? Vancocin Capsules should be taken as directed by your physician. The usual dose in adults is 500 mg to 2 g administered by mouth in 3 or 4 divided doses for 7 to 10 days. The usual dosage in pediatric patients is a daily dosage of 40 mg/kg divided into 3 or 4 doses for 7 to 10 days. The total daily dose in children should not exceed 2 g. Skipping doses or not completing the full course of therapy may decrease the effectiveness of the immediate treatment and increase the likelihood that bacteria will develop resistance and will not be treatable by Vancocin Capsules or other antibacterial drugs in the future. What are the possible side effects of Vancocin Capsules? For a full description of side effects, precautions, and contraindications associated with Vancocin Capsules click here. How are Vancocin Capsules supplied? Vancocin Capsules are available only by prescription. Vancocin Capsules are available as a 125 mg and 250 mg capsule. For full prescribing information, click here. VANCOCIN HCl Capsules may be administered orally for treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by Clostridium difficile. Parenteral administration of vancomycin is not effective for the above indications; therefore, VANCOCIN HCl Capsules must be given orally for these indications. Orally administered VANCOCIN HCl Capsules are not effective for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancocin Capsules and other antibacterial drugs, Vancocin Capsules should only be used to treat or prevent infections that are proven or strongly suspected to be caused by a susceptible bacteria. When culture and sensitivity are available, they should be considered in selecting or modifying antibacterial therapy. Adverse events include nephrotoxicity, ototoxicity, reversible neutropenia, thrombocytopenia, and “Red Man’s Syndrome”. In patients with renal dysfunction or those receiving concomitant therapy with an aminoglycoside, serial renal function testing should be performed. In patients receiving concomitant therapy with another ototoxic agent, serial tests of auditory function may be helpful in order to minimize the risk of ototoxicity. Infrequently allergic reation, including anaphylaxis, and exfoliative dermatitis have been reported. Clinically significant serum concentrations of vancomycin have been reported in some patients treated with Vancocin capsules for pseudomembranous colitis caused by Clostridium difficile. It is noteworthy that total systemic and renal clearance of vancomcyin are reduced in the elderly. Monitoring of serum concentrations may be appropriate in patients with renal insufficiency and/or colitis. Vancocin capsules are contraindicated in patients with a known hypersensitivity to vancomycin.